https://doi.org/10.4081/itjm.2022.1560

Independent correlation between ischemia modified albumin and parathormone in hemodialysis patients

Vol. 16 No. 1 (2022)
Submitted: 5 December 2022
Accepted: 29 December 2022
Published: 30 December 2022
Ischemia modified albumin, hemodialysis, oxidative stress, chronic kidney disease, bone mineral disease, parathormone.
Abstract Views: 1077
PDF: 219
HTML: 21
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Kenan Güçlü
https://orcid.org/0000-0002-0092-652X
Biochemistry Department, Kayseri State Hospital, Kayseri, Turkey.
Kağan Tur
kaantur542@gmail.com
https://orcid.org/0000-0001-5989-2099
Internal Medicine Department, Faculty of Medicine, Ahi Evran University, Kırşehir, Turkey.
Serdar Şahin
General Surgery Department, Faculty of Medicine, Ahi Evran University, Kırşehir, Turkey.
Aydın Güçlü
Nephrology Department, Faculty of Medicine, Ahi Evran University, Kırşehir, Turkey.

Hemodialysis patients are the group which oxidative stress is found more exacerbated. Ischemia modified albumin (IMA) is a new and sensitive marker for ischemia and oxidative stress. At current study we evaluated relation between IMA and biochemical parameters in hemodialysis patients. Thirty-four patients on maintenance hemodialysis were included. Prehemodialysis and post-hemodialysis blood samples were taken. Serum IMA and biochemistry parameters were measured. There was a positive correlation between alkaline phosphatase (ALP) and IMA (r=0.268, P<0.05), CRP and IMA (r=0.452, P=0.007), parathormone and IMA (r=0.436, P=0.010), There was a negative correlation between albumin and IMA (r= –0.338, P=0.05). Multiple regression analysis was run to predict IMA levels from parathormone, CRP and creatinine the model statistically significantly predicted relation P<0.05, R=0.506, out of four two variables added statistically significant to the prediction, PTH (P=0.006), CRP (P=0.029). In multiregression analysis, IMA was found to be associated with PTH and CRP independent of creatinine value. We showed for the first time that PTH is associated with IMA in hemodialysis patients, independent of the level of renal function.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative stress in hemodialysis patients: a re-view of the literature. Oxid Med Cell Longev 2017; Article ID 3081856.
Duni A, Liakopoulos V, Rapsomanikis K, Dounous E. Chronic kidney disease and dispropor-tionally increased cardiovascular damage: does oxidative stress explain the burden? Oxid Med Cell Longev 2017; Article ID 9036450.
Toraman A, Aras F, Hekimsoy Z, Kursat S. Is there a relationship between parathyroid hor-mone and neutrophil lymphocyte ratio or platelet lymphocyte ratio? Acta Endocrinol (Buchar) 2019;5:96-101.
Cheng SP, Liu CL, Liu TP, et al. Association between parathyroid hormone levels and in-flammatory markers among US adults. Mediat Inflamm 2014; Article ID 709024.
Lütfioğlu M, Sakallioğlu U, Sakallioğlu EE, et al. Dietary-induced hyperparathyroidism af-fects serum and gingival proinflammatory cytokine levels in rats. J Periodontol 2010;81:150-7.
Tanaka M, Tokunaga K, Komaba H, et al. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2011;15 161-8.
Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes–review and clini-cal implications. Clin Chem Lab Med (CCLM) 2011;49:177-84.
Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 2010;23:335-40.
Albarello K, Santos GA, Bochi GV, et al. Ischemia modified albumin and carbonyl protein as potential biomarkers of protein oxidation in hemodialysis. Clin Biochem 2012;45:450-4.
Duarte MM, Rocha JB, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009;42:666-71.
Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement thera-py. Semin Dial 2009;22:636-43.
Duni A, Liakopoulos V, Roumeliotis S, et al. Oxidative stress in the pathogenesis and evolu-tion of chronic kidney disease: untangling Ariadne’s thread. Int J Mol Sci 2019;20:3711.
Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. Oxidative stress in hemodialysis. Semin Dialysis 2018;970.
Noyan T, Avci G, Şekeroğlu M, Erkoç R. The investigation of relationship between second-ary hyperparathyroidism and oxidative stress in patients with chronic kidney disease. Turkish Nephrol Dialysis Transplant J 2009;18:69-75.
Cichota LC, Moresco RN, Duarte MM, Silva JE. Evaluation of ischemia‐modified albumin in anemia associated to chronic kidney disease. J Clin Lab Analysis 2008;22:1-5.
Sharma R, Gaze D, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502.
Bar-Or d, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med 2000;19:311-5.
Nepal M, Jaisawal S, Gragain M, et al. Ischemic modified albumin (IMA) as a novel marker for ischemic heart disease and surrogate marker for other high oxidative-ischemic conditions. J Cardi-ovasc Dis Res 2017;8.
Menon B, Ramalingam K, Krishna V. Study of ischemia modified albumin as a biomarker in acute ischaemic stroke. Ann Neurosci 2018;25:187-90.
Omma A, Sandikci SC, Colak S, et al. Serum calprotectin and ischemia modified albumin lev-els as markers of disease activity in Behçet's disease. Postepy Dermatol Alergol 2018;35:609-13.
Hakkoymaz H, Nazik S, Seyithanoğlu M, et al. The value of ischemia-modified albumin and oxidative stress markers in the diagnosis of acute appendicitis in adults. Am J Emerg Med 2019;37:2097-3001.
Reddy SV, Suchitra MM, Pradeep V, et al. Ischemia-modified albumin levels in overt and subclinical hypothyroidism. J Endocrinol Invest 2015;38:885-90.
Sunnetcioglu A, Asker S, Alp HH, Gunbatar H. Increased asymmetric dimethylarginine and ischemia-modified albumin levels in obstructive sleep apnea. Respir Care 2016;61:1038-43.
Mehmetoglu I, Yerlikaya H, Kurban SS, et al. Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemia-modified albumin. Int J Artif Or-gans 2012;35:226-32.
Turkmen K, Tonbul HZ, Toker A, et al. The relationship between oxidative stress, inflamma-tion, and atherosclerosis in renal transplant and end-stage renal disease patients. Renal Failure 2012;34:1229-37.

How to Cite

Güçlü, K., Tur, K., Şahin, S., & Güçlü, A. (2022). Independent correlation between ischemia modified albumin and parathormone in hemodialysis patients. Italian Journal of Medicine, 16(1). https://doi.org/10.4081/itjm.2022.1560
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.